Anixa Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AB</div>
ANIX -- USA Stock  

USD 2.37  0.04  1.72%

Anixa Biosciences Price to Sales Ratio is fairly stable at the moment as compared to the past year. Anixa Biosciences reported Price to Sales Ratio of 352.30 in 2019. Sales per Share is likely to rise to 0.012 in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (14.4 M) in 2020. Today's short post will break down Anixa Biosciences as your potential position. We will inspect the question of why investors should continue to be confident in Anixa Biosciences outlook.
Published over a week ago
View all stories for Anixa Biosciences | View All Stories
What can we learn from Anixa Biosciences (NASDAQ:ANIX) current price fluctuation
This firm has a beta of -0.1223. Let's try to break down what Anixa's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Anixa Biosciences will likely underperform. The beta indicator helps investors understand whether Anixa Biosciences moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Anixa deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Anixa Biosciences. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Anixa Biosciences


How important is Anixa Biosciences's Liquidity

Anixa Biosciences financial leverage refers to using borrowed capital as a funding source to finance Anixa Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Anixa Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Anixa Biosciences's total debt and its cash.

How Anixa utilizes its cash?

To perform a cash flow analysis of Anixa Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Anixa Biosciences is receiving and how much cash it distributes out in a given period. The Anixa Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Anixa Biosciences Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Anixa Biosciences reported Net Cash Flow from Operations of (4.27 Million) in 2019

Purchase by Lewis Titterton of 40000 shares of Anixa Biosciences

Legal trades by Anixa Biosciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Anixa insider trading alert for perchase of common stock by Lewis Titterton, the corporate stakeholder, on 14th of September 2020. This event was filed by Anixa Biosciences Inc with SEC on 2020-09-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Anixa Biosciences Indicators

Anixa Biosciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Anixa Biosciences independently to ensure intended market timing strategies are aligned with expectations about Anixa Biosciences volatility.

Returns Breakdown

Return on Assets(1.65)
Return on Equity(1.87)
Return Capital(7.89)
Return on Sales(43.03)

Our perspective of the current Anixa Biosciences rise

Current kurtosis is at 2.3. Anixa Biosciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Anixa Biosciences independently to ensure intended market timing strategies are aligned with expectations about Anixa Biosciences volatility.

The Bottom Line

While some other entities within the diagnostics & research industry are still a little expensive, even after the recent corrections, Anixa Biosciences may offer a potential longer-term growth to investors. To conclude, as of the 4th of September 2020, our ongoing 30 days advice on the company is Cautious Hold. We believe Anixa Biosciences is currently undervalued with average chance of financial distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Anixa Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com